You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

IT STARTS WITH

FINDING A REGIMEN THAT YOUR PATIENT PREFERS

Every-2-month VOCABRIA + REKAMBYS was preferred by 9 out of 10 trial patients vs daily oral therapy with BIC/FTC/TAF1

Alt text

preferred every-2-month VOCABRIA + REKAMBYS (secondary endpoint; n=382/425)*1

At Month 12, participants in the every-2-month VOCABRIA + REKAMBYS arm of the SOLAR study (mITT-E population) responded to a questionnaire assessing their preference for HIV treatment.1

*Out of the 447 participants in the every-2-month VOCABRIA + REKAMBYS arm, 425 responded; 90% preferred every-2-month VOCABRIA +
REKAMBYS; 5% preferred daily oral therapy with BIC/FTC/TAF; and 5% reported no preference.1

TOP FIVE REASONS SELECTED BY THOSE WHO PREFERRED EVERY-2-MONTH VOCABRIA + REKAMBYS IN THE SOLAR STUDY (n=382):1

85%

I do not have to worry as much about remembering to take my HIV medication every day

83%

It is more convenient for me to receive injections every 2 months

75%

I do not have to carry my HIV medication with me

61%

I do not have to think about my HIV status every day

59%

I do not have to worry about others seeing or finding my HIV pills

How would you start the conversation with one of your patients?

QUESTIONS THAT COULD UNCOVER CHALLENGES WITH DAILY ORAL HIV THERAPY:

Alt text

DO YOU HIDE YOUR MEDICATION FROM THOSE AROUND YOU?

Alt text

DO YOU FIND IT STRESSFUL TO REMEMBER TO TAKE YOUR TREATMENT EVERY DAY?

Alt text

HOW OFTEN DO YOU THINK ABOUT YOUR HIV?

BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; HIV=human immunodeficiency virus; mITT-E=modified intention-to-treat exposed; PLHIV=people living with HIV.

References
  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 

©2023 GSK group of companies. All rights reserved.

PM-IE-CBR-WCNT-230012
Date of preparation: December 2023